In this issue of JAMA Oncology, Molinaro et al1 retrospectively assess the value of aggressive resection of glioblastoma (GBM) across molecular subtypes in a timely analysis. Both the large number of participants and the use of a significant development cohort and a multicenter validation cohort add strength to the findings.
Glioblastoma is the most common type of primary brain tumor and is also the most difficult to treat. Despite modern multimodal therapy including resection, radiotherapy, chemotherapy, and alternating electric fields, GBM remains one of the most aggressive and lethal cancers, with 5-year survival rates of less than 10%.2
Choi BD, Gerstner ER, Curry WT. A Common Rule for Resection of Glioblastoma in the Molecular Era. JAMA Oncol. 2020;6(4):503–504. doi:10.1001/jamaoncol.2019.6384
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.